A quantitative analytical standard guaranteed to meet MaxSpec® identity, purity, stability, and concentration specifications
货号:ajcx23700
CAS:347841-46-7
分子式:C24H36D4O4
分子量：396.6
溶解度:DMF: 10 mg/ml,DMSO: 10 mg/ml,DMSO:PBS(pH 7.2) (1:4): 0.2 mg/ml,Ethanol: 1 mg/ml
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Ursodeoxycholic acid-d₄(UDCA-d₄) is intended for use as an internal standard for the quantification of UDCA by GC- or LC-MS. UDCA is a secondary bile acid formedviaepimerization of chenodeoxycholic acid .^1,2UDCA is also a metabolite of lithocholic acid in human liver microsomes.³It inhibits taurocholic acid uptake in HeLa cells expressing recombinant sodium/taurocholate cotransporting polypeptide (NTCP) with an IC₅₀value of 3.6 μM.⁴UDCA (50 μM) inhibits apoptosis induced by deoxycholic acid or ethanol in primary rat hepatocytes.⁵Dietary administration of UDCA blocks DCA-induced increases in the number of TUNEL-positive hepatocytes in rats. Formulations containing UDCA have been used in the treatment of primary biliary cirrhosis.

1.Dawson, P.A., and Karpen, S.J.Intestinal transport and metabolism of bile acidsJ. Lipid Res.56(6)1085-1099(2015) 2.Chiang, J.Y.L.Bile acid metabolism and signaling in liver disease and therapyLiver Res.1(1)3-9(2017) 3.Deo, A.K., and Bandiera, S.M.3-Ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acidDrug Metab. Dispos.37(9)1938-1947(2009) 4.Kim, R.B., Leake, B., Cvetkovic, M., et al.Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activityJ. Pharmacol. Exp. Ther.291(3)1204-1209(1999) 5.Rodrigues, C.M.P., Fan, G., Ma, X., et al.A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbationJ. Clin. Invest.101(12)2790-2799(1998)